Pharvaris N.V. (PHVS)

#SHOWTIME European Academy of Allergy and Clinical Immunology Congress (June 12-15) Scheduled to appear: $JSPR, $PHVS, $UPB

$KALV - Kalvista is still a buy ahead of their PDUFA $PHVS - Pharvaris is a hold well ahead of their HAE activity in 2026 $PHAR - I would sell or avoid this. Pharming will likely lose market shares or valuation with Kalvista’s expected approval & continued rise

🚀 Big catalyst day coming up on June 4th! 📅 Looks like $AKRO and $PHVS both have major Phase 3 data readouts ahead: $AKRO is expecting results for EFX targeting MASH (metabolic dysfunction-associated steatohepatitis) – market cap $4.09B, solid POA at 65%. $PHVS has Deucrictibant data readout for hereditary angioedema (HAE) – smaller cap at $964M but higher POA at 75%! Who’s watching these closely? Are you bullish or bearish? 📈🐂🐻 Let’s discuss your predictions in comments! #biotech #stocks #investing #FDA #catalyst #AKRO #PHVS

$PHAR surprised this is running up ahead of $KALV approval in HAE. GLL biotech investors but I would avoid PHAR $ $PHVS until Kalvista does their thing

$PHVS Pharvaris presents data supporting ongoing clinical development of deucrictibant Pharvaris announced a summary of data that were presented at the 14th C1-Inhibitor Deficiency and Angioedema Workshop. "Additional analyses of deucrictibant data demonstrate consistency in the clinical profile shown in both the prophylactic and on-demand treatment settings," said Berndt Modig, Chief Executive Officer of Pharvaris. "Deucrictibant's early-onset and durable treatment response in the on-demand setting, the maintenance of attack reduction for over a year and a half in the prophylactic setting, and the potential for deucrictibant to be used together in both the prophylactic and on-demand settings, if needed, provide additional evidence of deucrictibant's potential in the treatment of bradykinin-mediated angioedema. Pharvaris continues to diligently execute on the deucrictibant clinical program and is planning for two pivotal data readouts in the next 18 months."

Cantor Fitzgerald updates rating for Pharvaris ( $PHVS ) to Overweight, target set at 28 → 25.

$PHVS u will b impacted by RGTI

$PHVS CYDY

$PHVS. . CYDY

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Pharvaris BV. Is that bullish or bearish? $PHVS #RsiOverbought #NASDAQ

Cantor Fitzgerald has updated their rating for Pharvaris ( $PHVS ) to Overweight with a price target of 28.

$PHVS Pharvaris reports Q4 EPS (EUR 0.64) vs. (EUR 0.95) last year "Pharvaris is focused on the development of deucrictibant to address unmet needs for people living with bradykinin-mediated angioedema; our priority remains generating robust clinical data to support this goal. We are pleased to have met our aggressive enrollment timelines for RAPIDe-3; we believe this was driven by high engagement from the HAE community, reinforcing the excitement about the clinical data and the potential impact of deucrictibant for those with bradykinin-mediated angioedema," said Berndt Modig, Chief Executive Officer of Pharvaris. "To our knowledge, deucrictibant is the only orally-administered bradykinin B2 receptor antagonist in development for both the prophylactic and on-demand treatment of bradykinin-mediated angioedema. Consistent with the U.S. Food and Drug Administration, the European Commission's granting of orphan designation to deucrictibant reiterates its potential to address unmet medical needs in HAE, as well as other bradykinin-mediated angioedema diseases."

$PHVS Pharvaris Q4 2024 GAAP EPS €(0.64) Beats €(0.71) Estimate, Cash Balance Of €281M

$PHVS AGMH very good price to jump in at 0.042 has to get to a dollar soon if I post again mybad ........

$PHVS solid news no response yet from the market

We want to welcome Pharvaris to the upcoming Jones Healthcare and Technology Innovation Conference happening April 8-9 at the Venetian Resort in Las Vegas, NV. Pharvaris (Nasdaq: $PHVS) is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy and placebo-like tolerability with the convenience of an oral therapy to prevent and treat HAE attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/. We look forward to seeing the continued results from Berndt Modig, Stefan Abele, Annick Deschoolmeester, Anne Lesage, Peng Lu, David Nassif, Wim Souverijns, Anna Nijdam RA, Jochen Knolle, and the entire team. This event will bring together healthcare & technology companies, institutional investors, and industry experts for presentations, fireside chats, thematic panels, and one-on-one meetings. The Jones Healthcare and Technology Innovation Conference is a B2i Digital Featured Conference. See details and submit a registration request at https://b2idigital.com/jones-healthcare-and-technology-innovation-conference More details on participating companies, panel discussions, sponsors, and special events will be announced soon. Profiles of presenting companies and sponsors will be showcased on the Jones' B2i Digital Featured Conference page. For more information and to submit a registration request, visit: https://b2idigital.com/jones-healthcare-and-technology-innovation-conference *Requests are subject to approval Thank you to the team at Jones for organizing this event: Alan Hill, Packy Jones, Jack Terranova, Megan Bracero, Yuki Gonzalez, Rahul Patel, James O'Neill, Moe Cohen, Stephen Glagola, Bryan Turley, Matthew Brotman, Hans Vitzthum and many more exceptional leaders.

$PHVS $PKDC FDA SUBMISSION IS COMING 👇👇👇🔥🔥🔥

$PHVS News Article (PHVS) Technical Data https://marketwirenews.com/news-releases/-phvs-technical-data-5387428884016479.html $PHVS

Citizens Capital Markets has updated their rating for Pharvaris ( $PHVS ) to Market Outperform with a price target of 55.

$PHVS News How to Take Advantage of moves in (PHVS) https://marketwirenews.com/news-releases/how-to-take-advantage-of-moves-in-phvs--6467582498649662.html $PHVS

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Pharvaris BV. Is that bullish or bearish? $PHVS #RsiOversold #NASDAQ